100
Participants
Start Date
November 3, 2023
Primary Completion Date
June 30, 2027
Study Completion Date
June 30, 2027
TheraSphere Y-90 glass microsphere therapy
TheraSphere Y-90 glass microsphere therapy administered through the hepatic artery at index procedure.
Durvalumab (Imfinzi) immunotherapy
"1500 mg, every 4 weeks that continues for a maximum duration of 18 months or until confirmed progression (by site assessment), unacceptable toxicity, study withdrawal, or study early termination by the sponsor. Treatment beyond confirmed radiographic progression is permitted per patient consent if the following criteria are met:~* Absence of clinical symptoms or signs indicating clinically significant disease progression~* No decline in performance status~* Absence of rapid disease progression or threat to vital organs or critical anatomical sites (i.e. new CNS metastasis, respiratory failure due to tumor compression, spinal cord compression) requiring urgent alternative medical intervention~* No other treatment discontinuation criteria are met"
Tremelimumab immunotherapy
300 mg, single administration
University Hospital Geneva (HUG), Geneva
University Hospital of Bern, Bern
Columbia University Irving Medical Center, New York
Georgetown University, Washington D.C.
MedStar Washington Hospital Center, Washington D.C.
National Cancer Institute of Milan, Italy, Milan
Clinica Universidad de Navarra, Pamplona
Mayo Clinic, Jacksonville
Hospital Universitario Central de Asturias, Oviedo
CHU Montpellier, Montpellier
CHU Nantes, Rennes
CHU Grenoble, Grenoble
Hospital Universitari, Valencia
Clinico de Valladolid, Valladolid
CHU Angers - Hôpital Hôtel Dieu, Nantes
University of Minnesota, Minneapolis
Chru De Lille, Lille
Rush University Medical Center, Chicago
University of Chicago Hospital, Chicago
Washington University (Barnes-Jewish Hospital), St Louis
Ochsner Clinic Foundation, New Orleans
Intermountain Health, Salt Lake City
University of Arizona- Banner Health, Tucson
University of California San Diego, San Diego
Hôpital Beaujon, Clichy
Chu Henri Mondor, Créteil
University of California San Francisco, San Francisco
Hopital Paul Brousse, Villejuif
CHU de Bordeaux - Hôpital Haut-Lévêque, Clermont-Ferrand
CRLCC Eugene Marquis, Rennes
IRCCS - Regina Elena Cancer Institute, Roma
Azienda Sanitaria Universitaria Integrata Friuli Centrale (ASU FC), Udine
Hospital Gregorio Maranon, Madrid
Hospital Universitario Virgen de las Nieves, Madrid
Hospital. Ramon Y Cajal, Madrid
Hospital Clinic de Barcelona, Barcelona
Lead Sponsor
Biocompatibles UK Ltd
INDUSTRY
Boston Scientific Corporation
INDUSTRY